The Food and Drug Administration (FDA) has given the green light to the first-ever mRNA-based flu vaccine. Moderna announced this development on Wednesday evening, highlighting its potential impact in flu prevention.
This new vaccine targets individuals aged 50 and over. It represents a groundbreaking advancement in immunization methods by utilizing mRNA technology, similar to what was employed in several COVID-19 vaccines.
The approval comes amidst some controversy and public skepticism, notably from RFK Jr., regarding the use of mRNA technology. Despite this, Moderna expects the vaccine to be available at select retailers in the upcoming weeks.
“This approval marks a significant milestone in vaccine technology,” commented a Moderna spokesperson.
Through this development, the pharmaceutical industry is poised to provide an innovative solution for flu prevention, building on previous successes with mRNA technologies. The move signals an evolving landscape in the fight against respiratory illnesses.